Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018 (2018), Article ID 1823710, 6 pages
Research Article

The Utility of 18F-FDG PET/CT for Monitoring Response and Predicting Prognosis after Glucocorticoids Therapy for Sarcoidosis

1Department of Respiratory Disease, Daping Hospital, Third Military Medical University, Chongqing 400042, China
2Department of Nuclear Medicine, Daping Hospital, Third Military Medical University, Chongqing 400042, China

Correspondence should be addressed to Rongbing Jin and Yong He

Received 30 October 2017; Revised 22 January 2018; Accepted 24 January 2018; Published 1 March 2018

Academic Editor: Gernot Zissel

Copyright © 2018 Hengyi Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Sarcoidosis has significant heterogeneity involving multiple organs; treatment of the disease is a significant therapeutic challenge due to the difficulties in accurately monitoring disease activity and estimating prognosis. Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) plays an important role in assessing the metabolic activity. However, there is not enough evidence about the influence of this method in the clinical management and prognosis prediction for sarcoidosis. This study aims to investigate the clinical utility of 18F-FDG PET/CT for therapeutic evaluation and prognostic prediction in sarcoidosis. We had retrospectively enrolled 23 patients with sarcoidosis assigned to receive systemic glucocorticoids. All patients underwent baseline 18F-FDG PET/CT before initiating therapy and follow-up 18F-FDG PET/CT within 3 months after the therapy. The metabolic and clinical responses were classified. The baseline 18F-FDG PET/CT showed increased uptake in all patients. Based solely on biopsy-proven sites, the sensitivity of 18F-FDG PET/CT was 91.7%, and the sensitivity improved to 100% after excluding skin involvement. In the subsequent follow-up PET scans within 3 months after glucocorticoids therapy, the were variously decreased except one; there are significant differences in the clinical remission rates and the relapse rates between patients with a favorable response and cases with no response on follow-up PET scan, the increasing metabolic response was associated with the increase in clinical remission rates and the reduction in recurrence rates. In conclusion, the present study shows that 18F-FDG PET/CT is an effective way to monitor the early therapeutic reaction and is helpful in predicting the long-term prognosis of sarcoidosis.